Indias GLP1 market has already crossed Rs 1,000 crore in annualised sales, led by Novo Nordisks semaglutide portfolio and a rapid surge in Eli Lillys Mounjaro, underscoring the scale of demand Indian generic drugmakers are preparing to tap post2026
For optimal and long-lasting effects, a consistent treatment schedule is recommended
When you're ready to [Get Started Today] with your next project, know that the quality of your materials is our top priority, and we trust you'll make their handling yours
It's important to note that some medications and treatments, such as glutathione injections, may cause temporary numbness as a side effect
LY3298176, a novel dual GIP and GLP1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept